Conventional screening to rule out prostate cancer is based on a blood PSA test and a urological examination.
When any of these tests is altered, a biopsy is performed to confirm the diagnosis, where tissue samples from different areas of the prostate are analyzed.
Conventional biopsy is performed with ultrasound, but by itself does not serve to identify the location of the tumor, so the tissue takes are virtually random, this justifies that in a first biopsy are not diagnosed up to 30% of existing tumors and that new extractions of samples are necessary.
At MD Anderson Madrid we have the Histoscanning detection system that allows us to better locate the tumour and, therefore, direct the biopsy towards the suspicious areas, increasing the detection rate by up to 25%. Through the computer processing of the data obtained by conventional transrectal ultrasound, the system analyzes tissue variations caused by tumors and shows, on a color scale, the most suspicious areas.
While traditional biopsy diagnoses nearly 65% of prostate cancers, more sensitive techniques such as histoscanning can recognize up to 90% of tumors and, in cases of greater aggressiveness and volume, up to 95%.